Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Likely To Seek Women’s Health Partner For Endometriosis Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Neurocrine expects to carry development of its gonadotrophin-releasing hormone receptor antagonist through Phase IIb before partnering.

You may also be interested in...



Indiplon Driving Study Could Push Marketing Into High Gear

Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.

Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform

Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.

Regeneron COVID-19 Antibody Poised To Add Prevention Claim, Sub-Q Formula

The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.

Topics

UsernamePublicRestriction

Register

PS063964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel